Adeshwar Meditex Sets November 12 Board Meeting for Q2 Results

Adeshwar Meditex Ltd is scheduled to consider standalone unaudited results for the quarter and half year ended September 30, 2026, at its board meeting on November 12, 2026. The disclosure comes after the company reported ₹26.05 crore in sales and ₹0.53 crore in net profit for the half year ended March 2026.

When will Adeshwar Meditex announce its September 2026 results?

Adeshwar Meditex has scheduled a board meeting for Thursday, November 12, 2026, to consider and approve its standalone unaudited financial results for the quarter and half year ended September 30, 2026. The meeting is to be held through video conferencing mode, according to the board-meeting intimation.

The November 12 agenda covers both quarterly and half-yearly results. The company had earlier indicated that its board would consider financial results for the September 2026 period, while the specific meeting date was communicated later through the exchange disclosure.

The company has not disclosed the September 2026 financial figures in the material provided. Investors will therefore await the formal outcome of the board meeting for the latest sales, operating profit, net profit and earnings per share data.

Why has the trading window been closed?

Adeshwar Meditex closed its trading window from October 1, 2026, ahead of the consideration of the September-quarter and half-year results. The restriction applies to designated persons, including directors, promoters and associated entities identified under the company’s insider-trading compliance framework.

The window will reopen 48 hours after the declaration of the financial results. The company stated that this measure follows the SEBI (Prohibition of Insider Trading) Regulations, 2015, which restrict trading by insiders when they may possess unpublished price-sensitive information.

A trading-window closure does not indicate the direction of financial results. It is a standard compliance procedure used by listed companies before the announcement of periodic financial statements.

What do Adeshwar Meditex's latest reported half-year numbers show?

The latest reported standalone half-year figures in the provided data are for the period ended March 31, 2026, when Adeshwar Meditex recorded sales of ₹26.05 crore and net profit of ₹0.53 crore. Sales were lower than ₹30.06 crore in the half year ended September 30, 2025, while net profit declined from ₹0.73 crore.

Operating profit for the half year ended March 2026 stood at ₹1.23 crore, compared with ₹1.54 crore in the preceding reported half year. The operating profit margin was 4.72%, versus 5.12% for the half year ended September 2025. Interest expense declined to ₹0.25 crore from ₹0.36 crore over the same comparison.

The March 2026 half-year data also showed profit before tax of ₹0.81 crore, compared with ₹1.02 crore in September 2025. Earnings per share were ₹0.37 for the March 2026 half year, against ₹0.51 in the preceding half year.

What other board actions has Adeshwar Meditex taken in 2026?

Adeshwar Meditex’s board approved audited standalone financial results for the half year and financial year ended March 31, 2026, at a meeting held on May 21, 2026. The auditors issued an unmodified opinion on those financial results, according to the disclosures provided.

At the same stage of the company’s 2026 disclosures, the board approved a proposed equity fundraise of up to ₹40 crore. It also appointed Ms. Bhagyalaxmi Kavital as an Independent Director. The company had disclosed that its May 21 meeting would also take note of the internal audit report for the financial year ended March 31, 2026, and the resignation of Mr. Arun Koli as an Independent Director.

Shareholders subsequently considered company matters at Adeshwar Meditex’s 19th annual general meeting on September 23, 2026. The disclosed outcome stated that shareholders approved the financial statements and key appointments.

How does the November 12 meeting matter to investors?

The November 12 meeting is the next scheduled financial update for Adeshwar Meditex and will provide reported figures for the three and six months ended September 30, 2026. These results will allow investors to compare the company’s performance with the ₹30.06 crore sales and ₹0.73 crore net profit reported for the half year ended September 2025.

The latest available half-year figures showed lower sales, operating profit and net profit in the period ended March 2026 compared with the previous reported half year. The upcoming filing will provide the next verified reference point on whether those measures changed during the September 2026 period. Until the board outcome is filed, no conclusion can be drawn on the September-quarter performance.

The previously approved equity fundraise of up to ₹40 crore is also relevant to shareholders because it is a disclosed capital-raising proposal. The source material does not provide further details on the timing, structure or completion of the fundraise. Investors may monitor future exchange disclosures for updates alongside the financial-results announcement.

Conclusion

Adeshwar Meditex is due to consider its standalone September 2026 quarter and half-year financial results on November 12, with the trading window remaining closed until 48 hours after the announcement. The meeting follows reported sales of ₹26.05 crore, operating profit of ₹1.23 crore and net profit of ₹0.53 crore for the half year ended March 2026.

The immediate item to watch is the formal board-meeting outcome and the accompanying unaudited results for the period ended September 30, 2026. Further disclosures on the board-approved equity fundraise of up to ₹40 crore would also clarify the status of that proposal.